David A. Ricks

Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won’t derail Eli Lilly’s obesity market dominance

by
Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won’t derail Eli Lilly’s obesity market dominance

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Despite … Read more

Eli Lilly shares surge on new obesity pill data. What it means for the stock from here

by
Eli Lilly shares surge on new obesity pill data. What it means for the stock from here

Eli Lilly is tightening its grip on the lucrative weight-loss market as it moves into a new, more convenient phase that promises to broaden the appeal of its breakthrough drugs. The news Club name Lilly said its daily obesity pill was successful in a late-stage trial for Type 2 diabetes — sending shares soaring more … Read more